Safe To Treat HER2-positive Breast Cancer With Trastuzumab And Adjuvant Radiation, Study Finds

Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is trastuzumab (herceptin) -- typically used in combination with chemotherapy. However, a new study reports that it may be safe to treat these patients with both trastuzumab and adjuvant radiation therapy.

Read the whole article on Science Daily

More from Science Daily